Mark‐David Levin
- Geriatrics and Gerontology top 2%
- Hematology top 2%
- Multiple Myeloma Research and Treatments 24
- Chronic Myeloid Leukemia Treatments 10
- Blood groups and transfusion 10
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 46
- Oncology top 5%
- Peptidase Inhibition and Analysis 11
- HER2/EGFR in Cancer Research 9
- Physiology top 5%
-
- Lymphoma Diagnosis and Treatment 25
-
- Protein Degradation and Inhibitors 10
- Co-authors
- Hánah N. RierAgnes JagerStefan SleijferJoost van RosmalenArnon P. KaterAndrea B. MaierMarc C. J. M. KockPeter E. Westerweel
- Partner nations
- NetherlandsUnited StatesDenmark
In The Last Decade
Mark‐David Levin
107 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 97
- Geriatrics and Gerontology 167
- Hematology 431
- Genetics 405
- Oncology 655
- Physiology 391
Countries citing papers authored by Mark‐David Levin
This map shows the geographic impact of Mark‐David Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark‐David Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark‐David Levin more than expected).
Fields of papers citing papers by Mark‐David Levin
This network shows the impact of papers produced by Mark‐David Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark‐David Levin. The network helps show where Mark‐David Levin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark‐David Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 12 | |
| 7 | 2022 | 11 | |
| 8 | 2022 | 5 | |
| 9 | 2021 | 27 | |
| 10 | 2021 | 5 | |
| 11 | 2020 | 32 | |
| 12 | 2020 | 30 | |
| 13 | 2020 | 10 | |
| 14 | 2020 | 5 | |
| 15 | 2020 | 6 | |
| 16 | 2018 | 7 | |
| 17 | 2018 | 7 | |
| 18 | 2018 | 8 | |
| 19 | Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial | 2017 | 0 |
| 20 | 2016 | 123 |
About Mark‐David Levin
Mark‐David Levin is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Geriatrics and Gerontology and Oncology, having authored 109 papers that have together received 1.6k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (46 papers), Lymphoma Diagnosis and Treatment (25 papers), Multiple Myeloma Research and Treatments (24 papers), Peptidase Inhibition and Analysis (11 papers), Protein Degradation and Inhibitors (10 papers), Chronic Myeloid Leukemia Treatments (10 papers), Blood groups and transfusion (10 papers) and HER2/EGFR in Cancer Research (9 papers). The work is most often cited by research in Geriatrics and Gerontology (167 citations), Hematology (431 citations), Genetics (405 citations), Oncology (655 citations) and Physiology (391 citations). Mark‐David Levin has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Hánah N. Rier, Agnes Jager, Stefan Sleijfer, Joost van Rosmalen, Arnon P. Kater, Andrea B. Maier, Marc C. J. M. Kock, Peter E. Westerweel, Pieter Sonneveld and Eric Eldering. Their work appears in journals such as Blood, HemaSphere, Journal of Clinical Oncology, Blood Advances and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.